Arkolith/Insider Trading/ZNTL/Form 4

Lackner Mark

Chief Scientific OfficerZentalis Pharmaceuticals, Inc. (ZNTL) · full profile →Form 4 · filed Feb 5, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$25K
Net Open-Market Flow
-$25K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 3, 2025Grant(A)336K—$0527K
Feb 3, 2025Sell(S)14K$1.71$25K513K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 3, 2025Grant(A)125K—$0125K

Transaction Codes

A
Grant / award
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001725160-25-000041) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML